Vnitr Lek 2009, 55(Suppl 1):88-93

Problems of haemostatic disorders in metabolic syndrome

P. Galajda*, M. Mokáň
I. interná klinika Jesseniovej lekárskej fakulty UK a MFN Martin, Slovenská republika, prednosta prof. MUDr. Marián Mokáň, DrSc., FRCP Edin

Metabolic syndrome (MS) is defined as cluster of independent risk factors of coronary heart disease (CHD) and type 2 diabetes mellitus (DM2) including glucose metabolism disorders associated with insulin resistance, central obesity, dyslipidaemia with increasing of triglyceride levels and decreasing of high density lipoprotein levels and arterial hypertension. There are differences in prediction of CHD and DM2 risk among recommendations for diagnostic criteria of MS according to WHO (1999), NCEP-ATPIII (2001), ACE/AACE (2003), AHA/NHBLI (2004) and IDF (2005). New risk factors include markers of low grade inflammatory reaction, endothelial dysfunction and hypofibrinolytic state. Inflammatory parameters (C-reactive protein, fibrinogen) and endothelial markers (von Willebrand factor) are more important for prediction of CHD risk, while PAI-1 as marker of fibrinolytic disturbance is independent risk factor for DM2 development.

Keywords: metabolic syndrome; low grade inflammatory reaction; endothelial dysfunction; plasminogen activator inhibitor type 1

Received: April 8, 2009; Published: February 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Galajda P, Mokáň M. Problems of haemostatic disorders in metabolic syndrome. Vnitr Lek. 2009;55(Supplementum 1):88-93.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Galajda P. Metabolický syndróm. In: Mokáň M, Martinka E, Galajda P (eds). Diabetes mellitus a vybrané metabolické ochorenia. Martin: P+M 2008: 685-698.
    2. Alberti KGM, Zimmet FZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provinsional report of a WHO consultation. Diabet Med 1998; 15: 539-553. Go to original source... Go to PubMed...
    3. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497. Go to original source... Go to PubMed...
    4. Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) consensus conference on insulin resistance syndrome: 25-26 august 2002, Washington, DC. Diabetes Care 2003; 26: 1297-1303.
    5. Grundy SM, Brewer HB Jr, Cleeman JI et al. Definition of metabolic syndrome. Report of the National Heart, Lung and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004; 109: 433-438. Go to original source... Go to PubMed...
    6. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome (April 14 2005). Available from: www.idf.org/webdata/docs/Metab_syndrome_def.pdf.
    7. Tkáč I, Klimeš I, Krahulec B et al. Diagnóza a možnosti liečebného ovplyvnenia metabolického syndrómu. Vyjadrenie stanoviska panelu expertov odborných spoločností. Interná medicína 2005; 5: 239-242.
    8. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003; 26: 575-581. Go to original source... Go to PubMed...
    9. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993; 44: 121-131. Go to original source... Go to PubMed...
    10. Reaven GM. Syndrome X - past, present, and future. In: Draznin B, Rizza R (eds). Clinical Research in Diabetes and Obesity. Totowa, NJ: Humana Press, Inc 1998: 357-382. Go to original source...
    11. Lewis GF, Carpentier A, Adeli K et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23: 201-229. Go to original source... Go to PubMed...
    12. Fernández-Real JM, Ricart W. Insulin resistance and inflammation in an evolutionary perspectives: the contribution of cytokine genotype/phenotype to thriftiness. Diabetologia 1999; 42: 1367-1374. Go to original source... Go to PubMed...
    13. Permana PA, Menge C, Reaven PD. Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. Biochem Biophys Res Commun 2006; 341: 507-514. Go to original source... Go to PubMed...
    14. Yudkin JS, Kumari M, Humphries SE et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148: 209-214. Go to original source... Go to PubMed...
    15. Galajda P, Mokáň M. Poruchy hemostázy a diabetes mellitus. Martin: Prokonzult 2001: 1-255.
    16. Haffner SM. The metabolic syndrome: Inflammation, diabetes mellitus and cardiovascular disease. Am J Cardiol 2006; 97 (Suppl 2A): 3A-11A. Go to original source... Go to PubMed...
    17. Yudkin JS, Stehouwer CD, Emeis JJ et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-978. Go to original source... Go to PubMed...
    18. Lowe GD. Circulating inflammatory markers and risk of cardiovascular and non-cardiovascular disease. J Thromb Haemost 2005; 3: 1618-1627. Go to original source... Go to PubMed...
    19. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28: 2375-2414. Go to original source... Go to PubMed...
    20. Festa A, D'Agostino R Jr, Tracy RP et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 2002; 51: 1131-1137. Go to original source... Go to PubMed...
    21. Hanley AJ, Karter AJ, Festa A et al. Factor analysis of metabolic syndrome using directly measured insulin sensitivity. The Insulin Resistance Atherosclerosis Study. Diabetes 2002; 51: 2642-2647. Go to original source... Go to PubMed...
    22. Remková A. Protrombotický stav ako súčasť metabolického syndrómu. Vnitř Lék 2005; 51: 1120-1125.
    23. Fibrinogen Studies Collaboration: Collaborative meta-analysis of prospective observational studies of plasma fibrinogen and cardiovascular disease. Eur J Cardiovasc Prev Rehabil 2004; 11: 9-17. Go to original source... Go to PubMed...
    24. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: A clinical perspective. Endocr Rev 2001; 22: 36-52. Go to original source... Go to PubMed...
    25. Charles MA, Morange P, Eschwège E et al. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the prevention of the risk of obesity. Diabetes Care 1998; 21: 1967-1972. Go to original source... Go to PubMed...
    26. Mertens I, Van Gaal LF. Obesity, haemostasis and fibrinolytic system. Obes Rev 2002; 3: 85-101. Go to original source... Go to PubMed...
    27. Sakkinen PA, Wahl P, Cushman M et al. Clustering of procoagulation, inflammation and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000; 152: 897-907. Go to original source... Go to PubMed...
    28. Lijnen HR, Alessi MC, Van Hoef B et al. On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. J Thromb Haemost 2005; 3: 1174-1179. Go to original source... Go to PubMed...
    29. Bouchard L, Mauriège P, Vohl MC et al. Plasminogen activator inhibitor-1 polymorphisms are associated with obesity and fat distribution in the Quebeck Family Study: evidence of interactions with menopause. Menopause 2005; 12: 136-143. Go to original source... Go to PubMed...
    30. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005; 3: 1879-1883. Go to original source... Go to PubMed...
    31. Colwell JA, Nesto RW. The platelets in diabetes. Focus on prevention of ischemic events. Diabetes Care 2003; 26: 2181-2188. Go to original source... Go to PubMed...
    32. Pearson TA, Blair SN, Daniels SR et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases (AHA Scientific Statement). Circulation 2002; 106: 388-391. Go to original source... Go to PubMed...
    33. Colwell JA, American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2003; 26 (Suppl 1): S87-S88. Go to original source... Go to PubMed...
    34. Sacco M, Pellegrini F, Roncaglioni MC et al. PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients. Results of the primary prevention project (PPP) trial. Diabetes Care 2003; 26: 3264-3272. Go to original source... Go to PubMed...
    35. de Gaetano G, Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 89-95. Go to original source... Go to PubMed...
    36. Kubisz P, Mištuna D, Staško J et al. Poruchy krvných doštičiek. In: Malý J, Pecka M (eds). Trombóza a hemostáza. Hradec Králové: HK Credit 2007: 16.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.